Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody
Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.
Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe
European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.
Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.
Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?
GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from […]
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.
Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences
Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.
Sepsis breakthrough? What the EMBRACE trial reveals about Sobi’s emapalumab strategy
Swedish Orphan Biovitrum AB (Sobi) has reported positive topline data from the Phase 2a EMBRACE trial of Gamifant (emapalumab) in interferon-gamma-driven sepsis (IDS), demonstrating organ function improvement and a potential survival benefit. Based on the signal, the drug will advance in development in collaboration with the Hellenic Institute for the Study of Sepsis (HISS). The […]
Mabwell’s anti-ST2 antibody 9MW1911 cleared for U.S. Phase IIa trial: Could this reshape COPD biologics?
Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell […]